Impact of GPCRs in clinical medicine: Monogenic diseases, genetic variants and drug targets  by Insel, Paul A. et al.
Biochimica et Biophysica Acta 1768 (2007) 994–1005
www.elsevier.com/locate/bbamemReview
Impact of GPCRs in clinical medicine: Monogenic diseases, genetic variants
and drug targets
Paul A. Insel a,b,⁎, Chih-Min Tang a, Ines Hahntow c, Martin C. Michel c
a Department of Pharmacology, UCSD, La Jolla, CA 92093-0636, USA
b Department of Medicine, UCSD, La Jolla, CA 92093-0636, USA
c Department Pharmacology and Pharmacotherapy, AMC, University of Amsterdam, Netherlands
Received 27 July 2006; received in revised form 28 September 2006; accepted 29 September 2006
Available online 5 October 2006Abstract
By virtue of their large number, widespread distribution and important roles in cell physiology and biochemistry, G-protein-coupled receptors
(GPCR) play multiple important roles in clinical medicine. Here, we focus on 3 areas that subsume much of the recent work in this aspect of
GPCR biology: (1) monogenic diseases of GPCR; (2) genetic variants of GPCR; and (3) clinically useful pharmacological agonists and
antagonists of GPCR. Diseases involving mutations of GPCR are rare, occurring in <1/1000 people, but disorders in which antibodies are directed
against GPCR are more common. Genetic variants, especially single nucleotide polymorphisms (SNPs), show substantial heterogeneity in
frequency among different GPCRs but have not been evaluated for some GPCR. Many therapeutic agonists and antagonists target GPCR and
show inter-subject variability in terms of efficacy and toxicity. For most of those agents, it remains an open question whether genetic variation in
primary sequence of the GPCR is an important contributor to such inter-subject variability, although this is an active area of investigation.
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In addition to their large number, widespread expression and
important mechanistic and regulatory properties, as reviewed by
others in this volume, G-protein-coupled receptors (GPCR)
have well-recognized roles in clinical medicine. Their
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accessible, especially by hydrophilic hormones and drugs,
including both agonists and antagonists, and their non-
uniformity of expression in different tissues and cell types
provides selectivity (in some cases, specificity) in the targeting
of these receptors for the activation or blockade of physiological
events. Studies in recent years have provided a number of new
insights, many of them gleaned from application of the tools of
the "genetic revolution". In this article, we will review aspects
of GPCR in clinical medicine with an emphasis on recent
developments and insights in 3 areas: (1) monogenic diseases of
GPCR; (2) genetic variants of GPCR; and (3) clinically useful
pharmacological agonists and antagonists of GPCR. Each of
these are large topics that have been the subject of reviews in
recent years (e.g., [1–8]). We refer interested readers to such
reviews for additional information that length restrictions
prevent us from presenting in detail. Other sources of useful
information related to these topics include a variety of web-
based tools [9], including www.hapmap.org and sites accessible
therefrom.
2. Monogenic diseases of GPCR
Monogenic diseases and genetic variants associated with
those diseases are generally quite rare, occurring in <1% of the
population and often variably among subjects of different
ethnicities. Since GPCR comprise ∼3% of the human genomeTable 1
Examples of rare mutants of GPCR that cause human diseases
Receptor/Gene name Mutation
Calcium-Sensing (CaS)/ CaSR Multiple
(e.g. Arg185Gln)
CXCR4 Multiple
(e.g. Ser338X)
Endothelin receptor B (ETB)/EDNRB Multiple
(e.g. Trp276Cys)
Follicle-stimulating hormone (FSH)/FSHR Multiple
(e.g. Ala189Val)
N-formyl-peptide (FPR)/FPR1 Phe110Ser,
Cys126Trp
Frizzled (FZD4)/FZD4 Multiple
(e.g. Arg417Gln)
Gonadotropin-releasing hormone (GnRH)/GNRHR Multiple
(e.g. Arg262Gln)
GPR54 Multiple
(e.g. Cys223Arg)
GPR56 Multiple
(e.g. Cys223Arg)
vGPCR/KSHV-GPCR (constitutively active)
Relaxin family peptide receptor 2 (RXFP2)/LGR8 Multiple
(e.g. Thr222Pro)
MASS1 (also called VLGR1, USH2C) Multiple
(e.g. Ser2652X)
Melanocortin (MC4)/MC4R Multiple
(e.g. Pro78Leu)
Rhodopsin/RHO Multiple
(e.g. Pro23His)
Vasopressin receptor (V2)/AVPR2 Multiple
(e.g. Arg113Trp)[10], it is perhaps not surprising that non-lethal mutations can
occur in GPCR, especially those that are expressed in sensory
and hormonal systems, where they serve as mediators of
information transfer from the extracellular environment to the
cell interior. One such critical action is in the visual system
where rhodopsin in photoreceptor-expressing neurons, retinal
rods and color (red, blue and green) opsins in retinal cones,
transduce the input from photons of light into electrical
impulses that then travel to the brain and are decoded. A
second major class of physiologically important GPCR are
those that mediate the action of hormones, especially polypep-
tide hormones but also including the action of hormones, such
as the calcium-sensing receptor (CaSR) or receptors for other
chemical entities (e.g., lipids, amines, fatty acids). A third class
is receptors for physiologically important neurotransmitters,
such as norepinephrine (and to a lesser extent, epinephrine),
acetylcholine (at muscarinic cholinergic receptors), dopamine,
serotonin (at certain receptors), glutamate (at metabotrophic
receptors) as well as numerous peptides and lipids that function
as neuromodulators. To date, mutations that lead to human
disease have been identified in a relatively limited number of
GPCR. We will briefly discuss 3: rhodopsin, V2 vasopressin and
the calcium-sensing receptor.
A large number of monogenic mutations have been
identified in rhodopsin, in particular in patients that have the
disease retinitis pigmentosa; in addition, a number of hormon-
ally responsive GPCR have been identified as pathologicDisease Ref
Autosomal Dominant Hypocalcemia (ADH)
Sporadic Hypoparathyroidism
Familial Hypoparathyroidism
[15,90]
WHIM syndrome [91,92]
Hirschsprung's disease [93]
Female infertility [94]
Juvenile periodontitis [95]
Familial exudative vitreoretinopathy (FEVR) [96,97]
Hypogonadotropic hypogonadism (HH) [98, 99]
Hypogonadotropic hypogonadism (HH) [98,99]
Bilateral frontoparietal polymicrogyria (BFPP) [100,101]
Kaposi's sarcoma (KS) [102,103]
Cryptorchidism [104–106]
Usher syndrome, Febrile seizures (FS) [107–110]
Dominant and recessive obesity [111,112]
Retinitis pigmentosa (RP) [113–115]
Nephrogenic diabetes insipidus (NDI) [116,117]
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disorders include those with either activating mutations or
mutations that block hormonal response. Studies that docu-
mented hormone resistance in patients with particular disorders
were often critical in focusing attention on GPCR or their
signaling pathways as the sites of lesions in such disorders,
whereas in other situations excessive response in the absence of
increased levels of the activating hormones provided a similar
impetus to infer a role for components and events that mediate
hormonal response.
The location of clinically (i.e., pathophysiologically) sig-
nificant mutations are not always sites that have been suspected
from mutational analyses with cloned receptors. As shown in
Fig. 1, which highlights the sites that are mutated in rhodopsin,
a wide variety of residues have been identified in patients with
retinitis pigmentosa, a leading cause of blindness and visual
disability in younger people that occurs with an overall
frequency of one in 4000. Retinitis pigmentosa is a disorder
that leads to the progressive death of the rod photoreceptors;
recent work suggests that such cell death may be a consequence
of a high, constant rate of signal transduction that causes the
rods to die, perhaps secondary to prolonged lowering of Ca2+
concentration [11].
Nephrogenic diabetes insipidus (NDI), which results from
failure of vasopressin (antidiuretic hormone, ADH) to act on the
renal collecting duct to facilitate water reabsorption, is another
well-studied monogenic disorder of a GPCR, the arginine
vasopressin receptor 2 (AVPR2, V2), in which mutations cause
congenital nephrogenic diabetes insipidus in ∼90% of patientsFig. 1. Schematic structure of rhodopsin. Each amino acid residue is shown as a green
shown as red dots. Seven transmembrane domains are boxed. Mutations are colle
Information Network (www.sph.uth.tmc.edu/RetNet/sys-dis.htm), and the Retina In
htm) and references [88] and [89].via an X-linked recessive mode of inheritance [12]. To date,
>280 families with a history of NDI have been shown to have
>180 putative disease-causing mutations in AVPR2 (Fig. 2 and
[12]). In most cases, these mutations lead to the intracellular
trapping of the V2 receptors, such that few receptors reach the
plasma membrane to trigger the activation of Gs and adenylyl
cyclase and thereby, the generation of cAMP. Therapeutic
approaches are under investigation that involve the use of
nonpeptide V2 receptor antagonists to bind intracellular
receptors as what have been termed “pharmacochaperones”
that will facilitate their folding, insertion and function in the
plasma membrane [13].
Rhodopsin belongs to Family A, which contains the largest
group of GPCR superfamily members; receptors in this Family
generally contain a relatively short extracellular N-terminus and
highly conserved amino acids within each transmembrane
domain. Family A members are activated by small ligands such
as biogenic amines and nucleotides, although rhodopsin itself is
stimulated by photons of light that activate a retinal bound in a
transmembrane pocket. In contrast, the V2 receptor belongs to
Family B, whose receptors recognize large peptides and are
generally characterized by longer N-termini, in the case of V2
receptors one that has six conserved cysteine residues.
Comparison of rhodopsin and the V2 receptor (Cf. Figs. 1
and 2) reveals that disease-causing mutations occur in all
portions of the two receptors with a greater number in
transmembrane domains relative to mutants in non-transmem-
brane domains of V2 receptors in NDI than of rhodopsin in
retinitis pigmentosa.dot; amino acid residues that are mutated in patients with retinitis pigmentosa are
cted from the Human Gene Mutation Database (www.hgmd.org), the Retinal
ternational Mutation Database (www.retina-international.com/sci-news/rhomut.
Fig. 2. Schematic structure of the vasopressin V2 receptor (AVPR2). Each amino acid residue is shown as a green dot; amino acid residues that are mutated in patients
with nephrogenic diabetes insipidus are shown as red dots. Seven transmembrane domains are boxed. Mutations found in the AVPR2 gene were collected from the
Human Gene Mutation Database (www.hgmd.org) and the Diabetes Insipidus Mutation Database (www.medicine.mcgill.ca/nephros).
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monogenic disease in GPCR [14,15]. This receptor is found on
numerous tissues involved in calcium homeostasis, including
the parathyroid glands, kidney, and intestine. Binding of calcium
to the CaSR is the mechanism by which parathyroid cells detect
changes in ionized calcium concentration and in turn, modulate
parathyroid hormone secretion so as to maintain serum calcium
levels within a narrow physiologic range. CaSRs in renal tubules
modulate calcium reabsorption in response to alterations in
extracellular calcium concentrations. Several hypocalcemic and
hypercalcemic disorders have been identified that derive from
rarely occurring mutations of CaSR: loss-of-function CaSR
mutations in the hypercalcemic disorders of familial benign
(hypocalciuric) hypercalcaemia (FHH, FBH or FBHH) and
neonatal severe primary hyperparathyroidism (NSHPT) (each of
which occur <1/10,000) and gain-of-function CaSR mutations
in autosomal dominant hypocalcaemia with hypercalciuria
(ADHH) and Bartter's syndrome type V.
In addition to such “classical” monogenic diseases, another
type of such disease can involve the generation of antibodies
as monoclonal (or polyclonal) expansion of immune cells with
the antibody products directed against GPCR or in some cases,
their downstream targets. The most prevalent example is
Graves disease, a form of hyperthyroidism with enhanced
response to thyroid-stimulating hormone (TSH) that is most
commonly secondary to autoimmune activation of TSH
receptors [16,17]. Another example of activating (as well as
inhibitory) antibodies directed at GPCR (e.g., β-adrenergic
and muscarinic cholinergic) is Chagas' cardiomyopathy, whichis triggered by infection with the protozoan Trypanosoma
cruzi [18,19].
In several other settings, antibodies directed at GPCR can
blunt hormone action, preventing G-protein activation (e.g.,
[15,17,20–24]). Of note, such disorders are almost invariably
ones that occur in adults rather than children whereas
monogenic disorders of the receptors themselves often manifest
clinical abnormalities much earlier in life.
3. Genetic variants of GPCR
Completion of the human genome has introduced a large
amount of DNA sequence information that predicts 367 non-
sensory GPCRs and an additional 380 or more chemosensory
GPCRs [25]. Human genomic data also reveal that GPCR loci
harbor a substantial number of genetic variants, including
nucleotide insertion or deletion as well as the exchange of a
single nucleotide, i.e. single nucleotide polymorphisms (SNPs).
SNPs account for ∼80% of all sequence variations and
generally occur at a frequency ∼1 in 1200 nucleotides. A
polymorphism is defined as a genetic variant that occurs at a
locus with an allelic frequency of greater than or equal to 1%
whereas “mutations”, such as those discussed in the prior
section, designate rarer genetic variants that are germline-
transmitted changes in a given individual or somatic variation
identified in isolated tissues.
Genetic variants/polymorphisms identified in GPCRs can
influence receptor expression, targeting, function, and receptor
turnover; as well as the ability of receptors to recognize and
Table 2
Examples of polymorphisms of GPCR associated with human diseases
Receptor Polymorphisms Examples of disease associations Ref
β1 Adrenergic receptor Arg389Gly Heart failure [64,71]
β2 Adrenergic receptor Multiple Hypertension, Asthma [118,119]
β3 Adrenergic receptor Trp64Arg Obesity [120]
CC chemokine receptor 2 (CCR2) Val64Ile Delayed progression of AIDS [121]
CC chemokine receptor 5 (CCR5) Multiple Associated with progression of AIDS [33,122]
Dopamine receptor 2 (D2) 3′UTR52A/G Associated with depression and anxiety [123]
Dopamine receptor 3 (D3) Ser9Gly, Promoter SNPs Haplotype associated with schizophrenia [124]
Muscarinic receptor subtype 3 (M3) Promoter haplotype Possible association with asthma and atopy [125]
Neuropeptide S receptor
(NPSR; also called GPR154, GPRA)
Haplotypes H1, H5, Asn107Ile, rs324981 Asthma susceptibility [31,32,126]
P2Y12 CA deletion at Codon 240 Associated with bleeding diathesis [127]
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GPCRs with polymorphisms involved in human diseases, in
addition to elucidating their potential for serving as future
therapeutic targets. Table 2 lists sequence variants identified in
human GPCR genes that relate to human diseases.
The β2-adrenergic receptor possesses multiple polymorph-
isms, including several in the coding region and 5′ untranslated
region, that generate 4 common haplotypes (collections of va-
riants) in different ethnic groups (Caucasian, African-American,
Hispanic-Latino and Asian) [26]. Two common (i.e., occur
>20%) non-synonymous polymorphisms, Arg16Gly and the
Gln27Glu, have been shown to influence regulation of receptors
by agonists but not receptor binding or coupling to Gs/adenylyl
cyclase. Individuals who are Arg16 homozygotes display
slower/impaired bronchodilatory response upon agonist activa-
tion of the β2-adrenergic receptor than do people who are Gly16
homozygotes [27,28]. Such results suggest that Arg16Gly may
predict β2-adrenergic receptor agonist response in the therapy of
asthma, although additional studies are needed [29]. Other
recent data obtained with patients from the UK indicate that such
variants do not contribute in a major way to asthma incidence or
prevalence [30].
Another candidate GPCR associated with asthma suscept-
ibility was recently de-orphanized and named the neuropeptide
S receptor (NPSR), formerly known as orphan receptor GPRA
or GPR154 [31]. One non-synonymous SNP, Asn107Ile, has a
strong association with asthma but with as-yet no clear evidence
to explain the genetic association. Melen et al. studied 7
polymorphisms of NPSR and inferred 7 haplotypes (H1-H7) in
a case-control study of childhood allergy and asthma and found
that haplotypes H1 and H5 were significantly associated with
asthma [32].
The best studied example of genetic variants in a GPCR
functioning as disease modifier is the CC chemokine receptor-5
(CCR5) [33]. This receptor plays a crucial role in HIV-1
pathogenesis, serving as a co-receptor for viral entry and CCR5
polymorphisms, including promoter SNP (59029A/G) and a
deletion of 32 base pairs (Δ32), influence progression of HIV
infection to AIDS. CCR5Δ32 causes a frame shift at amino acid
185 leading to a premature termination of the receptor between
putative transmembrane domains IV and V [33]; whereas
promoter SNP 59029G shows lesser activity than 59029A allele
by in-vitro promoter reporter assay [34]. Thus both CCR5Δ32and 59029G SNP seem to be protective in HIV infection due to
lower expression of CCR5 receptors on the cell surface.
Significant progress has been achieved in recent years in
identifying genetic polymorphisms of GPCR's and in providing
suggestive evidence of their relevance in various human
diseases, in addition to yielding information regarding mechan-
isms of GPCR signal transduction. Given the complexity of this
receptor superfamily, including structural heterogeneity, recep-
tor multiplicity, and redundancy in signaling pathways, further
efforts will be required to identify and document definitively the
contributing role of polymorphisms in disease and as disease
modifiers. There is as-yet incomplete information regarding the
full-range of genetic variants of most GPCRs, including orphan
GPCRs, and thus this is likely to remain an area of active
research with potential clinical importance. In addition, two
aspects of such variants that have not yet been well explored
include the possible role of synonymous SNPs that may change
the binding and action of exon splicing enhancer (ESE) proteins
and thus affect RNA splicing even though they do not produce
amino acid substitutions [3,35] and the potential contribution of
genetic variants in GPCR coding sequences that will alter the
ability of receptors to oligomerize [36]. Studies of GPCR
variants should be aided by the completion of the HapMap [37]
and identification of tag SNPs for particular haplotypes in genes
of interest [38].
4. Drug effects and the role of genetic variants of GPCR
As a class, GPCR have been the most successful molecular
drug targets in clinical medicine. Agonists and antagonists of
GPCR are used in the treatment of diseases of every major
organ system including the CNS, cardiovascular, respiratory,
metabolic and urogenital systems. Certain GPCRs have been
particularly useful as drug targets. These include AT1
angiotensin, adrenergic, dopamine and serotonin (5-hydroxy-
tryptamine, 5-HT) receptor subtypes as well as GPCR for
hormones whose activity is increased or decreased in particular
endocrine disorders. For example, antagonists of AT1 angio-
tensin II receptors are used to prevent diabetes mellitus-induced
renal damage [39] and to treat essential hypertension and
congestive heart failure. α1-Adrenergic receptor antagonists are
employed for symptomatic treatment and to slow the clinical
progression of benign prostatic hyperplasia [40]. β-adrenergic
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tors, increase survival in patients with congestive heart failure
[41] and are used to treat essential hypertension and coronary
heart disease. β2-adrenergic receptor agonists are a cornerstone
in the treatment of asthma and chronic obstructive pulmonary
disease and are used to delay preterm labor [42]. Dopamine
receptor antagonists, primarily via their actions on D2 receptors,
are standard therapeutic agents in the treatment of schizo-
phrenia, although some representatives of this class may exert
antipsychotic effects via other dopamine receptor subtypes and/
or 5-HT receptors [43]. Dopamine receptor agonists (e.g.,
levodopa serving as a precursor for dopamine) are widely used
to treat Parkinson's disease [43]. Inhibitors of 5-HT uptake act
as indirect agonists at various subtypes of 5-HT receptors and
are used to treat major depressive disorders; several of these
subtypes may also be involved in the effects of atypical
antipsychotic drugs.
While most GPCR are expressed in a tissue-selective
manner, it remains a key challenge for the safe use of drugs
to identify compounds that will selectively act on a particular
receptor in a target tissue and largely spare those receptors in
other tissues, thereby potentially minimizing side effects. Such
tissue selectivity may result from pharmacokinetic phenomena
(e.g. distribution and metabolism) [44] but may also involve
tissue-specific expression of GPCR splice variants and/or
receptor oligomers [45,46].
Responses to drugs target to GPCRs can show substantial
inter-subject variability. Attempts to use clinical factors as a
means to predict individual drug responses have had limited
success. Therefore, much recent attention has involved assess-
ment of genetic features that potentially influence variability in
drug responses. Genetic variations of enzymes or transporters
involved in the pharmacokinetics of drugs [47,48] and
polymorphisms of GPCR genes have been investigated as
possible determinants of heterogeneous drug responses.
GPCR polymorphisms may have tissue-, cell type- or ligand-
specific effects on drug responses. Apart from the possibility of
response-specific physiological counter-regulatory mechan-
isms, factors intrinsic to the biochemical properties of
polymorphic receptors may contribute to such heterogeneity.
Tissue-selective factors may relate to the differential expression
of specific biochemical properties in different cell types. For
example, the human α1A-adrenergic receptor can couple to the
activation of extracellular signal-regulated kinases in Chinese
hamster ovary cells [49] but to its inhibition in rat-1 fibroblasts
[50]. Such differences are not yet well documented for a large
number of GPCR polymorphisms but may have specific
consequences in different cell types and tissues. Although
such differences in tissue selectivity are primarily expected
from genetic variants that affect the coding region of a gene
and/or its splicing, polymorphisms in the promoter region of
GPCR genes may affect transcription in a tissue-selective
manner [51].
GPCR polymorphisms not only may demonstrate tissue-
specificity but also may act in a ligand-specific manner, termed
“ligand-directed signaling”, whereby activation of a given
GPCR by two chemically distinct ligands leads to differentialsignaling responses [52]. Indeed, some GPCR polymorphisms
can affect functional responses to some but not other ligands,
e.g. with β3-adrenergic receptors [53–55]. Such concepts may
apply not only to acutely measured GPCR responses but also to
receptor regulation, especially because certain GPCR poly-
morphisms alter such regulation [56]. In the following we
illustrate these principles based upon examples from several
drug classes acting on GPCR that are frequently used in clinical
medicine (Table 3).
4.1. Angiotensin II receptors
Administration of AT1 antagonists to patients with high
blood pressure can lower blood pressure, increase glomerular
filtration rate and decrease cardiac hypertrophy. The most
widely investigated AT1 receptor polymorphism, A1166C SNP,
is located in an untranslated part of exon 5; its functional
relevance for the biology of AT1 receptors is unclear. This SNP
has been associated with enhanced responses to antagonists of
AT1 receptors or inhibition of angiotensin converting enzyme
(and hence a reduction of endogenous agonist) [57–59].
However, whenever more than one study has been reported
for a given response parameter, studies without significant
differences [60–62] or even with a significant difference in
favor of the opposite allele have been reported [63].
Thus, currently available data do not allow definitive
conclusions regarding the role of the A1166C SNP of the AT1
receptor but do point to some general notions. Firstly, all of the
above studies included relatively small numbers of patients
(<100 in most cases) and hence probably are statistically
underpowered. Second, searches for the role of a SNP for which
functional correlates are not known at the molecular and cellular
level are difficult to interpret, as such SNPs may only be
indicative of other genetic variants, including SNPs or extended
haplotypes, with which they are in linkage disequilibrium.
Thirdly, efforts that emphasize a single SNP outside the coding
region may not readily allow inferences that link gene structure
to function.
4.2. Adrenergic receptors
α1-Adrenergic receptor antagonists are the most frequently
used for the medical treatment of lower urinary tract symptoms
related to benign prostatic enlargement. Various SNPs have
been detected in the genes encoding the three α1-adrenergic
receptor subtypes [1,3,64]. However, the SNPs reported thus far
have only limited effects on protein function [65] and have not
been found to associate with clinical responses to α1-adrenergic
receptor antagonists [66].
β-Adrenergic receptor antagonists are widely used in several
disorders, including the treatment of hypertension, congestive
heart failure, angina pectoris and myocardial infarction. Studies
on a role of β1-adrenergic receptor polymorphisms in the
response to such drugs have focused on the non-synonymous
SNPs Ser49Gly and Arg389Gly. Multiple studies have reported
increased β1-antagonist effects associated with Arg389 [67–
71], an allele exhibiting an increased function in vitro [72],
Table 3
GPCR as drug targets: some examples of the impact of receptor polymorphisms
Receptor Drugs and some key indications Polymorphisms Relevance Ref
AT1 angiotensin II
receptor
Antagonists (e.g. losartan) in the treatment
of essential hypertension or congestive
heart failure
A1166C SNP in untranslated part
of exon 5
Inconclusive data for drug
responses where multiple
studies have been done
[57–63]
α1A-adrenergic
receptor
Antagonists (e.g. tamsulosin) to treat
micturition (bladder emptying) disorders
associated with enlarged prostate glands
C1475T Short- and long-term antagonist
effects apparently not affected
[66]
β1-adrenergic receptor Antagonists (e.g. propranolol, atenolol,
metoprolol, carvedilol) to treat essential
hypertension or congestive heart failure
Ser49Gly, Arg389Gly Arg389 linked to increased
antagonist effect
[60,67–69,
73,128]
β2-adrenergic receptor Agonists (e.g. terbutaline, salbutamol,
formoterol, salmeterol) for treatment of
obstructive airway disease or premature labor
Arg16Gly, Gln27Glu, Thr164Ile Possibly reduced responses with
Ile164 otherwise no consistent
association with drug responsiveness
[56]
D2 dopamine receptor Antagonists (e.g. haloperidol and clozapine)
to treat schizophrenia
-141C Ins/Del, Taq1A Reduced antagonist response with
Del or homozygous A2 allele.
[75–77]
Agonists (e.g. levodopa) for the treatment of
Parkinson's disease
No consistent associations with
therapeutic response or side
effects of agonists
D3 dopamine receptor Antagonists (e.g. haloperidol) in the
treatment of schizophrenia
Ser9Gly Increased risk of tardive
dyskinesia with Gly allele
[75,76]
5-HT2A receptor Antagonists (e.g. clozapine) to
treat schizophrenia
T102C Reduced response to
clozapine with C allele
[76,82]
Indirect agonists (e.g. fluvoxamine) for
the treatment of depression
Possibly reduced response to
agonists with homozygous T allele
5-HT2C receptor Antagonists (e.g. clozapine) to treat
schizophrenia
Multiple polymorphisms in
promoter and coding region in
linkage disequilibrium
Genotypes associate with
therapeutic response and with
side effects such as tardive
dyskinesia and weight gain
[81,83]
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contrast, no association has been observed in most studies of
β1-adrenergic receptor antagonist responses with the Ser49Gly
SNP, which also alters function in vitro [60,67,70,73].
Selective β2-adrenergic receptor agonists are used as
bronchodilators in patients with obstructive airway disease and
as tocolytic agents in women with premature labor. Three β2-
adrenergic receptor nonsynonymous SNPs have been studied:
Arg16Gly, Gln27Glu, and Thr164Ile. Although the position 16
and 27 variants are expressed both heterozygously and
homozygously, homozygous Ile164Ile subjects have not been
identified, implying that this is a lethal variant. Many studies
have tested the impact of these SNPs on agonist responses but
have yielded inconsistent findings with the exception of a lower
response of the rarer (found in <5% subjects) Ile164 genotype
[56]. However, as noted above, recent data have indicated that
asthmatic patients with the Arg16 variant shows less response to
short- or long-acting β2-adrenergic receptor agonists than do
patients with Gly16β2-adrenergic receptors [27–29]. Numerous
inconclusive studies have reported an association of these SNPs
with arterial hypertension [51] but recent data with a large
population sample document association of the Arg16 variant
with higher diastolic blood pressure but only in males, implying
an interaction of gender with this variant in regulation of blood
pressure [74]. The relevance of such a finding for the overall
population may be limited since the effect appears to be small
and gender-specific.
In conclusion, the emerging picture from studies of
adrenergic receptor SNPs is that most have little effect onligand recognition or receptor function in vitro and limited
influence on drug responsiveness in vivo. SNPs that affect the
sensitivity for receptor regulation by agonists, e.g. the
Arg16Gly and Gln27Glu SNPs in the β2-adrenergic receptor,
have yielded inconsistent results in terms of functional effects
and disease associations in vivo. In contrast, altered drug
responsiveness has been observed for certain SNPs that affect
receptor function in vitro, e.g. the β1-adrenergic receptor
Arg389Gly SNP and the infrequent Thr164Ile SNP in the β2-
adrenergic receptor with thus far less definitive evidence for
other β2-adrenergic receptor variants [29]. The findings high-
light the need to carefully test the biochemical consequences of
SNPs in vitro in order to enhance understanding of their
potential role in clinical association studies.
4.3. Dopamine receptors
Dopamine receptor antagonists are used clinically as
antipsychotic agents but frequently associated with side effects
such as tardive dyskinesia and weight gain. It was initially
believed that such agents act primarily via D2 receptors but
some atypical antipsychotics have also been shown to act via D3
receptors or 5-HT receptors (see below). By contrast,
Parkinson's disease, which involves brain region-specific
depletion of dopamine neurons, is treated with dopamine
receptor agonists and compounds such as levodopa that are
metabolized to dopamine receptor agonists.
Various studies have investigated a possible role of
polymorphisms in dopamine receptor genes in the treatment
1001P.A. Insel et al. / Biochimica et Biophysica Acta 1768 (2007) 994–1005of schizophrenia [75–77]. Such studies have found that both the
Del allele of the -141C Ins/Del polymorphism and the
homozygous A2 allele of the Taq1A polymorphism of the D2
receptor gene are associated with reduced therapeutic responses
to both typical antipsychotics (e.g., haloperidol) and atypical
antipsychotics (e.g., clozapine). Recent studies confirm such
findings [78,79]. Although side effects of typical antipsycho-
tics, such as the motor disorder tardive dyskinesia, are
classically linked to D2 receptors, studies that have assessed
for these polymorphisms have not yielded consistent associa-
tions. Tardive dyskinesia has instead been linked to the Ser9Gly
polymorphism of D3 receptors [75–77]. The same SNP has also
been associated with therapeutic response to the atypical
antipsychotic risperidone [80]. By contrast, few studies are
available regarding polymorphisms of D2 and D3 receptors;
therapeutic responses or side effects of agonists have not
yielded consistent associations. In aggregate, studies of
dopamine receptor polymorphisms have suggested that the
presumed molecular target of a drug may not always be the best
candidate for polymorphisms association studies, thus empha-
sizing anew that a drug may have molecular targets distinct
from those generally assumed to mediate its effect.
4.4. 5-HT receptors
Classical antipsychotics (e.g., haloperidol) are thought to be
dopamine receptor antagonists while atypical antipsychotics
(e.g., clozapine) have similar or even higher affinity for 5-HT
receptor subtypes. 5-HT receptors are also indirectly targeted by
5-HT uptake inhibitors such as fluoxetine, i.e. drugs that
increase the availability of 5-HT in the synaptic cleft. Such
uptake inhibitors are a cornerstone in the treatment of major
depressive disorders. Therapeutic responses and/or side effects
of both drug classes have been associated with polymorphisms
in the genes for 5-HT receptor subtypes, with most attention
focused on 5-HT2A and 5-HT2C receptors [76,77,81,82].
5-HT2A receptors may be involved in the response to atypical
antipsychotics and to 5-HTuptake inhibitors. The T102C SNP in
the 5-HT2A receptor gene has been associated with altered drug
responses: the C allele associating with a reduced response to
antagonists and the homozygous T allele with reduced response
to agonists [76,82]. Multiple polymorphisms, including a−1027
(GT) repeat in the promoter and a Cys23Ser SNP in the coding
region, exist in the gene for the 5-HT2C receptor and are in
linkage disequilibrium [81]. Although all studies are not
consistent, some of these polymorphisms, and certain haplo-
types thereof, appear to be associated with differences in the
therapeutic response to atypical antipsychotics and in the
production of side effects such as tardive dyskinesia and weight
gain [81,83].
5. Conclusions and perspective
Given their large number, widespread expression and roles in
the regulation of virtually every organ system throughout the
body, GPCR are physiologically important in maintaining
homeostasis, in particular via their ability to mediate responsesto circulating hormones and neurotransmitter input in the
central, peripheral and autonomic nervous systems. The cloning
and characterization of GPCR and of components involved in
mediating receptor responses and in regulating receptor
expression has provided a number of new insights, only some
of which have been exploited in clinical medicine. For example,
the physiologic agonists and functional role for a large number
of orphan GPCR remain unknown, although such orphan
receptors may prove to be as important—perhaps more so—
than GPCR currently emphasized in physiologic and pharma-
cologic studies and in drug development [84–86]. Newly
identified receptors (initially “orphans”) in the cloning era have
already yielded pharmacologically useful drugs, for example
CaSR agonists (calcimimetics) and antagonists (calcilytics) as
therapies for a variety of disorders [87].
A number of monogenic diseases of GPCR have been
defined, most thoroughly retinitis pigmentosa and NDI (Figs. 1
and 2), and these have provided useful insights regarding the
roles of particular residues and in the disease-causing potential
of GPCR mutations. Other disorders that involve antibodies to
GPCR are more common and have had a larger overall impact
on clinical medicine.
In spite of an ever-expanding identification of genetic
variants of GPCR, in particular SNPs, many studies on
associations of GPCR polymorphisms with disease or drug
responses are difficult to interpret because the specific
consequences of particular polymorphisms have not been
unequivocally established at the molecular and cellular level
and because most clinical studies are statistically underpowered
to allow robust conclusions. Perhaps polymorphisms have
stronger effects on therapeutic and adverse effects of their
ligands than on disease because any given GPCR plays a larger
role for specific drugs acting on a GPCR than for a complex
disease with multiple genetic and non-genetic determinants.
GPCR polymorphisms have yielded numerous interesting
mechanistic results, in particular by identifying residues not
necessarily implicated as functionally important prior to their
identification in sequencing studies of polymorphic receptors.
To date, however, most associations are too weak to allow
clinically meaningful predictions of GPCR variants and their
relationship to disease onset or progression or in drug responses
(the results with Arg389Gly SNP in the β1-adrenergic receptor
being an exception [60–64]). Additional data are clearly needed.
GPCR will continue to be highly important in clinical
medicine because of their large number, wide expression and
role in physiologically important responses. We speculate that
future discoveries will reveal new GPCR drugs, in part because
it is relatively easy to screen for pharmacologic agents that
access these receptors and stimulate or block receptor-mediated
biochemical or physiological responses. In addition, further
insights into GPCR biology may reveal novel, unexpected
therapeutic targets that influence the GPCR life cycle or “ligand
directed signaling”. The existence of a large number of orphan
GPCRs provides a treasure trove of possibilities. Our bias is that
the full flowering of genetic studies of GPCR variants and their
clinical role has yet to be realized. Thus, we would argue, “let
the future begin!”
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